CymaBay Therapeutics shares are trading higher after the company announced the FDA revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect the treatment of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis.